I N T R O D U C T I O N
Fractures are an important cause of morbidity and mortality in patients on renal replacement therapy (RRT) [1] . Histological changes of bone disease begin early in chronic kidney disease (CKD), but the clinical consequences of bone pain and fracture occur mainly in CKD stage 5d. Features specific to CKD-mineral bone disease (MBD) (hyperphosphataemia, diminished activation of vitamin D, secondary hyperparathyroidism, elevated fibroblast growth factor-23) and exposure to medications altering bone metabolism in patients with CKD are likely to contribute to fracture risk. Markers of CKD-MBD improve substantially with successful renal transplant (RT), but transplant patients have the additional fracture risk associated with steroid-induced osteoporosis. The true fracture risk in RRT patients and its association with surrogate markers of CKD-MBD are poorly defined.
In a recent report of the temporal trends in fracture risk in a large cohort of dialysis patients, the incidence of pelvic/hip fractures fell from 29.6 per 1000 patient-years in year 2000 to 20.6/ 1000 patient-years in 2009 [2] . A systematic review looking into fracture risk in kidney transplant recipients with follow-up from 1.7 to 5.3 years found a variable incidence rate of 3.3-99.6 fractures per 1000 person-years [3] . The methods of detecting fracture events, difference in fracture definitions used and the fracture sites studied make it difficult to precisely define the true incidence and risk factors for fractures in the RRT population. The aim of this study was to quantify the incidence of radiologically proven bone fracture in all prevalent RRT groups and the relationship with associated risk factors.
M A T E R I A L S A N D M E T H O D S
All adults (>18 years of age) prevalent on RRT on 7 July 2010 were identified from the West of Scotland electronic patient record. This prospectively maintained database includes all patients managed by the four adult renal units [National Health Services (NHS) Ayrshire and Arran (n ¼ 287), NHS Dumfries and Galloway (n ¼ 123), NHS Greater Glasgow and Clyde (n ¼ 1376) and NHS Lanakshire (n ¼ 310) at inception] serving the 2.5 million people of the West of Scotland and has interfaces that receive all radiology reports from all of the 20 hospital radiology departments in the region. New fractures were identified by reviewing all radiology reports manually (X-ray, computerized tomography, magnetic resonance imaging, ultrasound, nuclear medicine scans, angiographic reports and others) and included all radiology investigations from the date of inception. The clinical indication for the radiological examination was used to determine if the fracture was likely new. Where it was unclear from the report if the fracture was new or old, a previous radiological investigation was viewed if available. Fractures reported in this study were either symptomatic or incidental findings reported as part of other radiological investigations for a different purpose. From the clinical indication included in the radiological reports, the vast majority of fractures identified were symptomatic.
This methodology meant that all fractures in the study patients would be identified with the exception of fractures occurring outside the region (e.g. if the patient was on vacation elsewhere). All of these reports were read by two authors (V.D. and T.E.F.) to identify new fracture events. If multiple anatomically distant sites were involved in one incident, then they were recorded as separate fracture events. The NHS Lanarkshire renal unit joined the West of Scotland renal electronic patient record in 2011, so 1 August 2011, selected as the inception date for RRT patients from this centre. The median follow-up for the whole cohort was 3.0 years.
Definition of fracture site
We based the grouping of anatomical fracture sites on International Classification of Diseases, 10th revision (ICD-10) [4] (Table 1) .
Covariates
Covariates identified as potential risk factors for fractures were age, sex, primary renal disease (PRD), RRT modality, RRT duration, biochemical parameters [serum albumin, phosphate, adjusted calcium, alkaline phosphatase, intact parathyroid hormone (PTH)], haemoglobin and medications affecting bone metabolism [corticosteroids, cinacalcet, alfacalcidol, calcium and non-calcium-containing phosphate binders (non-CCPBs)].
For the calculation of biochemical parameters, the average of the last three results prior to inception was calculated. The predialysis values performed routinely each month were used for patients on haemodialysis (HD). The ERA-EDTA Coding System for Primary Renal Disease and the related web-based PRD search tools were used in recording the diagnosis of PRD [5] . They were grouped as familial/hereditary nephropathies, glomerular disease, systemic disease, tubulointerstitial disease and diabetes.
Statistical analysis
Follow-up continued until the date of death or date of last recorded serum laboratory result in the electronic record before 4 September 2013. The incidence of fracture was expressed as the total number of fractures per 1000 patient-years of followup. Patient baseline characteristics and fracture risk ratio (RR) were compared between RRT modalities. The risk for subgroups was the total number of fractures divided by the total follow-up time in that group and RRs with 95% confidence intervals (CIs) were calculated to compare groups.
Actuarial time to first fracture was calculated by KaplanMeier survival method and log-rank test applied to determine statistical differences between RRT groups. Censor date was the time to first fracture, death or lost to follow-up. Survival analyses were studied for different fracture groups: all fractures, hip fractures, pelvic fractures and major fractures (femur, hip and pelvic fractures combined).
Cox proportional hazard models were constructed with time to first fracture as the dependent outcome. The hazard ratio (HR) for fractures was estimated for each covariate in the univariable model. All covariates in the univariable model were selected for the multivariable model. Further multivariable models were created in the same way for the RT and HD groups separately. Statistical analysis was performed using SPSS version 21 (IBM, Armonk, NY, USA). P-values <0.05 were regarded as statistically significant.
Institutional review board or ethics committee oversight and Declaration of Helsinki
This study involved anonymous, observational, electronic data collection and thus no ethical approval or informed consent was sought. 
Patient characteristics
We identified 2096 patients on RRT at the start of the study: 907 on HD, 108 on peritoneal dialysis (PD) and 1081 had a functioning RT. The mean age at inception was 55.7 years (50.4 years for the RT group and 61.8 years for the HD group). The median duration of subsequent follow-up was RT 1112 days (range 8-1155), HD 1086 days (range 1-1155) and PD 1126 days (range . Patient characteristics at study inception are provided in Table 2 . As expected, mean serum phosphate, PTH and alkaline phosphatase were lowest in the RT group, and this group also had the highest haemoglobin concentration. Prevalent corticosteroid use was highest in the RT group and prevalent phosphate binder and activated vitamin D use was highest in the HD group.
Incidence of fractures
There were 340 fractures in the 3-year study period with an overall incidence of 62.8 per 1000 patient-years. The incidences were 37.6, 99.2 and 57.6 per 1000 patient-years in the RT, HD and PD groups, respectively (P < 0.05). Radial, foot and hip fractures were the three most common sites (n ¼ 53, 47 and 46, respectively). Fractures at other sites are illustrated in Table 3 .
The RR of fracture in the HD group compared with the RT group was 2.60 (95% CI 2.59-2.61), and in the HD group compared with the PD group, the RR was 1.70 (95% CI 1.68-1.70) for all fracture types. Figure 1 shows Kaplan-Meier cumulative hazard plots for first fracture based on RRT modality. Patients with RT had lower risks than HD and PD patients for all fractures (median time to first fracture 492, 464 and 588 days, respectively). Subanalysis of time to first hip fracture, pelvic fracture and all major fractures (hip, pelvis and femoral studied cumulatively as a group) showed similar results (data not shown). This risk difference was not seen for femoral fractures (P ¼ 0.77) (not shown). Age (HR 1.03 per year), female gender (HR 1.60), HD (HR 2.58), diabetes (HR 2.38), serum phosphate (HR 1.73 per mmol/L), alkaline phosphatase (HR 1.0 per IU/mL), 
Univariable analysis

Multivariable model of all RRT groups
In the multivariable model including all RRT groups (Table 4) , age (HR 1.02, P ¼ 0.002) and HD (HR 5.25, P < 0.001) were independently associated with an increased risk of fractures and glomerular disease (HR 0.42, P ¼ 0.017), while increasing serum albumin (HR 0.96 per g/L, P ¼ 0.06) and being on alfacalcidol (HR 0.51, P ¼ 0.001) or lanthanum (HR 0.41, P ¼ 0.002) at inception were associated with decreased risk (Table 4) .
Multivariable model of the HD group
In a multivariable model of only HD patients, age (HR 1.03, P ¼ 0.003) was independently associated with reduced time to first fracture and glomerular disease (HR 0.36, P ¼ 0.026), while increasing serum albumin (HR 0.95 per g/L, P ¼ 0.041) and being on alfacalcidol (HR 0.54, P ¼ 0.008) or lanthanum (HR 0.46, P ¼ 0.05) at inception were associated with decreased risk.
Multivariable model of the transplant group
In a multivariable model of transplant patients, there were no significant independent associations of baseline co-variates with time to first fracture.
D I S C U S S I O N
Our study is the first that analyses all radiologically proven fractures, whether hospitalized or not, in patients on all RRT modalities. We found that the incidence of fracture of 62.8 per 1000 patient-years is almost double that reported in a selfreported health survey from 2002 to 2004 in a sample representative of the general population in the UK [6] and within the wide range of 3.3-99.6 per 1000 patient-years in previous reports in the RT population [3] . We found that the relative risk of fractures in RT patients was substantially lower compared with that of the dialysis population. This association remained even when adjusting for associated risk factors, including the younger age of transplant patients. Increasing age was independently associated with increased risk of fracture, while prescription of alfacalcidol or lanthanum at baseline was associated with reduced risk and there were no associations with baseline measures of CKD-MBD. The reduced incidence of fractures seen in the RT group is partly explained by selection bias, as the RT population is a healthier population, while the HD population was from an older age group with increased frailty and thus with an increased risk of falls. However, even when attempting to adjust for known risk factors, the incidence was reduced compared with dialysis patients despite the likely osteopaenic effects of corticosteroids in the RT population. In a separate multivariable analysis there was no association between study centre fracture incidence (data not shown).
CKD is associated with hyperphosphataemia, hypocalcaemia, increased PTH, reduced activation of vitamin D, inactivated vitamin D deficiency and uraemia. These result in abnormal micro-architectural bone changes at both the cortical and trabecular level [7, 8] , leading to renal osteodystrophy. Cortical bone plays a key role in providing mechanical strength [9, 10] , thus any changes in structure increase the risk of fracture. Lanthanum carbonate, a non-CCPB, improves renal osteodystrophy compared with other phosphate binders [11] . It increases mineralization at the periosteal surface and bone mass in HD patients with adynamic bone disease [12] . This has been proposed to reduce fracture risk, and our data provide some support for this, with lanthanum use at the time of study inception being independently associated with reduced fracture risk FIGURE 1: Kaplan-Meier curves. Time to first fracture based on RRT modality at baseline (P < 0.001, log-rank test). HD, haemodialysis; PD, peritoneal dialysis; RT, renal transplant. [11, 12] . Further exploration of this hypothesis would require detailed analysis of total exposure to phosphate binders, which was beyond the scope of this study. It is unlikely that a randomized controlled study of sufficient power will ever be conducted to test the hypothesis that lanthanum reduces fracture risk compared with other phosphate binders. In our cohort, lanthanum exposure was not random, but was determined by physician and patient preference. No association with lanthanum was seen in the RT group, but that may be explained by the fact that few patients in the RT group were on phosphate binders. Incident vertebral fractures were identified in 3.2% of our HD cohort, compared with a prevalence of 55.3% in a study of 387 patients by Fusaro et al. [13] . The authors in the study determined the prevalence of historical vertebral fractures in HD patients, irrespective of symptoms identified radiologically using specialized, quantitative vertebral morphology software (MorphoXPress), whereas we identified mainly the incidence of new symptomatic fractures [13] .
A recent secondary analysis of the Evaluation of Cinacalcet to Lower Cardiovascular Events (EVOLVE) trial in HD patients revealed an incidence of fractures of 47 per 1000 patient-years in the placebo arm [14] compared with 99.2 in our HD cohort. This may be explained by lower median age in the placebo arm compared with our HD group (54.4 versus 63.3 years), exclusion of patients with unstable medical conditions in the EVOLVE trial and fractures being identified by patient-reported clinical events from study centres [14, 15] . Cinacalcet use was associated with a 16-29% reduction in fractures [14] . We did not identify a significant association between fractures and cinacalcet, although only 12.1% of the HD cohort was on cinacalcet at study inception.
The role of vitamin D supplementation in patients with CKD and fracture prevention is not yet established. Vitamin D administration is associated with increased bone strength in animal models [16] and a prospective, randomized, placebocontrolled, double-blind study showed improved bone mineral density (BMD) assessed by dual energy X-ray absorptiometry (DEXA) with lowering of plasma PTH levels [17] . Although BMD assessment by DEXA in patients with end-stage renal disease has limitations [18, 19] , our study supports the putative protective role of activated vitamin D in preventing fractures in the HD group. The Dialysis Outcomes and Practice Patterns Study II study suggested high PTH levels might be an independent risk factor for fractures in HD patients [20] . PTH concentrations have a U-shaped relationship with vertebral and hip fractures, with no associations with pelvic fractures [21] . In contrast, our results were more consistent with the US Renal Data System Wave 1 data [22] , which did not find any such association of fractures with PTH levels.
Our data are also consistent with previous reports that have shown an association between the risk of fractures in the HD population with lower serum albumin [20] and no significant fracture association with serum calcium and phosphate [21] . It is interesting that we found no higher fracture incidence in females, unlike other reports in the RRT and general population [20, [22] [23] [24] .
Our study has limitations: we did not include factors such as race, body mass index, smoking status and ethnicity, which have previously been associated with fracture risks, as these data were not available and nearly all patients were Caucasian. PRD was available for only 1285 patients, which reduced the power of the analysis of this particular association. Exposure to medications was based on the data collected at the point of entry and did not account for cumulative exposure before or after study inception. We may have failed to detect a genuine association between fracture risk and factors such as haemoglobin and phosphate because adherence to treatment guidelines keeps these factors within relatively narrow ranges, meaning that the conclusions are limited to the ranges studied. We did not evaluate the role of previous RRT modalities (other than total duration on RRT before study), previous fractures, reasons for receiving a particular phosphate binder and exposure to other potentially relevant medication such as heparin. Incidental or silent fractures may have been missed. These limitations are inherent in observational studies of large prevalent cohorts.
Despite these limitations, we feel that the large population studied from multiple centres, absence of exclusions, access to all radiological reports and averaging of laboratory variables over three consecutive readings make our conclusions relevant to patients and clinicians and the data could be used to inform the power calculations of interventional prevention studies.
C O N C L U S I O N
The risk of symptomatic bone fracture is high in RRT patients and is $2.5 times higher in HD than in RT patients, with the increased risk being independent of baseline factors. Fracture risk increases with age and lower serum albumin and is reduced if the PRD is glomerular disease. The possible protective role of alfacalcidol and lanthanum in HD patients deserves further exploration.
C O N F L I C T O F I N T E R E S T S T A T E M E N T
The results presented in this article have not been published previously in whole or part, except in abstract format in the 51st and 52nd ERA-EDTA Congress.
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